NASDAQ:CALA - Calithera Biosciences Stock Price, Forecast & News

Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."

Calithera Biosciences Inc (NASDAQ:CALA) released its quarterly earnings results on Tuesday, November, 12th. The biotechnology company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.07. View Calithera Biosciences' Earnings History.

Calithera Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Calithera Biosciences.

3 equities research analysts have issued 12-month price targets for Calithera Biosciences' shares. Their forecasts range from $7.00 to $8.00. On average, they expect Calithera Biosciences' share price to reach $7.50 in the next twelve months. This suggests a possible upside of 1.2% from the stock's current price. View Analyst Price Targets for Calithera Biosciences.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Calithera Biosciences.

News stories about CALA stock have been trending extremely negative recently, according to InfoTrie. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Calithera Biosciences earned a media sentiment score of -5.0 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Calithera Biosciences.

Calithera Biosciences saw a decline in short interest in the month of December. As of December 13th, there was short interest totalling 1,660,000 shares, a decline of 12.6% from the November 28th total of 1,900,000 shares. Based on an average trading volume of 572,800 shares, the days-to-cover ratio is presently 2.9 days. Currently, 4.8% of the shares of the stock are short sold. View Calithera Biosciences' Current Options Chain.

Some companies that are related to Calithera Biosciences include Ligand Pharmaceuticals (LGND), Alder Biopharmaceuticals (ALDR), Esperion Therapeutics (ESPR), Amneal Pharmaceuticals (AMRX), Corcept Therapeutics (CORT), Innoviva (INVA), Dicerna Pharmaceuticals (DRNA), Intra-Cellular Therapies (ITCI), Theravance Biopharma (TBPH), BELLUS Health (BLUSF), Nabriva Therapeutics (NBRV), Endo International (ENDP), TG Therapeutics (TGTX), Madrigal Pharmaceuticals (MDGL) and Y-mAbs Therapeutics (YMAB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Calithera Biosciences investors own include Puma Biotechnology (PBYI), Medivation (MDVN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Celadon Group (CGI), Dynavax Technologies (DVAX), First Solar (FSLR), Camtek (CAMT), Plug Power (PLUG) and Exelixis (EXEL).

Shares of CALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CALA stock can currently be purchased for approximately $7.41.

Calithera Biosciences has a market capitalization of $398.51 million and generates $22.25 million in revenue each year. The biotechnology company earns $-54,630,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis. Calithera Biosciences employs 79 workers across the globe.View Additional Information About Calithera Biosciences.

The official website for Calithera Biosciences is http://www.calithera.com/.

Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-870-1000 or via email at [email protected]